Champions Oncology Advances Focus on Data and Discovery Partnerships with the Appointment of Dr Tammer Farid as General Manager of Champions’ Data Business
HACKENSACK, N.J., December 8, 2025, Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and translational oncology solutions provider, today announced that Tammer Farid, Ph.D., has joined the organization as General Manager of its Data Business.
In this role, Dr. Farid will lead and scale Champions’ data operations and product strategy, with a focus on how the company delivers its multiomic and functionalized tumor datasets to biopharma partners and works with them to advance their therapeutic programs. He will work across scientific, bioinformatics, and commercial teams to ensure Champions not only generates world class data but also turns deep tumor biology into practical tools that help drug developers design better studies, reduce clinical risk, and power AI-enabled discovery.
Champions’ data ecosystem is built on a living biobank of more than 2,000 low passage, patient-derived tumor models, extensively characterized across genomics, transcriptomics, proteomics, and functional assays. This real-world tumor biology is captured in its full complexity and structured for computation, giving drug developers access to clinically aligned datasets that support target discovery, translational hypothesis generation, model selection, and predictive modeling across oncology portfolios.
“Drug development teams are under enormous pressure to move faster while making better informed decisions,” said Rob Brainin, CEO of Champions Oncology. “Tammer’s experience at the intersection of data, technology, and life sciences is critical as we expand our data platforms, deepen our functional datasets, and make it easier for customers to integrate Champions’ data and services into their pipelines and AI tools. His strategic vision will help ensure our deep biological data translates into real value for our partners and ultimately for patients.”
Dr. Farid joins Champions from Illumina, where he directed the company-wide portfolio strategy and led a growing business focused on translational services for precision medicine development and implementation. Prior to Illumina, Dr. Farid was a Partner in Boston Consulting Group’s healthcare practice, advising global biopharma, diagnostics, and medical technology organizations on growth, innovation, and data strategy.
“Champions has built something unique in oncology - a deep, clinically anchored, and increasingly functionalized tumor dataset that reflects how cancer behaves in the real world” said Dr. Farid. “My focus is on making that data even more accessible and actionable for drug developers. That means tighter integration with our preclinical platforms and solutions that support everything from early target exploration to AI model training and late-stage portfolio decisions.”
For more information about Champions Oncology data solutions, including its multiomic datasets, please contact us or learn more here.